S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid Leukemia

• Distribution of topoisomerase 2 (TOP2) expression and single nucleotide polymorphisms [ Time Frame: immediate ] [ Designated as safety issue: No ]
• Distributions of mutations in TOP2 phosphorylation sites [ Time Frame: immediate ] [ Designated as safety issue: No ]
• Correlation of TOP2 expression with complete remission rates, relapse-free survival, and overall survival [ Time Frame: immediate ] [ Designated as safety issue: No ]
• Variation of TOP2 expression and mutations in TOP2 phosphorylation sites among patients and disease characteristics [ Time Frame: immediate ] [ Designated as safety issue: No ]

• Distribution of topoisomerase 2 (TOP2) expression and single nucleotide polymorphisms [ Designated as safety issue: No ]
• Distributions of mutations in TOP2 phosphorylation sites [ Designated as safety issue: No ]
• Correlation of TOP2 expression with complete remission rates, relapse-free survival, and overall survival [ Designated as safety issue: No ]
• Variation of TOP2 expression and mutations in TOP2 phosphorylation sites among patients and disease characteristics [ Designated as safety issue: No ]

RATIONALE: Studying samples of bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is looking at biomarker expression in bone marrow samples from patients with acute myeloid leukemia.

OBJECTIVES:

• Estimate the distributions of topoisomerase 2 (TOP2) expression and single nucleotide polymorphisms (SNPs) in patients with newly diagnosed acute myeloid leukemia (AML).
• Estimate the distributions of mutations in TOP2 phosphorylation sites (by SNP analysis) in these patients.
• Investigate whether expression of TOP2 or mutations in TOP2 phosphorylation sites vary with patient or disease characteristics in these patients.
• Test whether TOP2 expression correlates with complete remission rates, relapse-free survival, and overall survival of these patients.
• Conduct preliminary analyses to estimate the distributions of TOP2 expression and mutations in TOP2 phosphorylation sites (by SNP analysis) in patients with relapsed and/or refractory AML.
• Investigate whether expression of TOP2 and mutations in TOP2 phosphorylation sites vary with patient or disease characteristics in patients with relapsed and/or refractory AML.
• Test whether TOP2 expression and mutations in TOP2 phosphorylation sites differ between previously untreated and relapsed/refractory AML patients.

OUTLINE: This is a multicenter study.

Archived RNA specimens are analyzed for topoisomerase 2 transcriptional expression by quantitative real-time polymerase chain reaction (PCR) and for mutations within TOP2 phosphorylation sites by single nucleotide polymorphism analysis.

patients enrolled on S0931, S9126, S9333 or S9500 consenting to use of specimens for future research

• Genetic: DNA analysis
• Genetic: RNA analysis
• Genetic: mutation analysis
• Genetic: polymerase chain reaction
• Genetic: polymorphism analysis
• Other: laboratory biomarker analysis

DISEASE CHARACTERISTICS:

• Diagnosis of acute myeloid leukemia

  • All subtypes allowed (except acute promyelocytic leukemia [M3])
  • Previously untreated OR relapsed/refractory disease
• Isolated RNA specimens from bone marrow aspirate samples available from patients who participated on SWOG-9031, SWOG-9333 (cytarabine/daunorubicin hydrochloride induction arm only), SWOG-9500, or SWOG-9126

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics